Preventing RSV is of extreme importance since the acquisition of the pathogen early in life, which involves the lower respiratory tract, is linked with an increasing risk of both asthma in adolescence or later and COPD in adult age. Susanna Esposito, President WAidid, underlines that studies on the safety and efficacy of vaccines against RSV are ongoing: in particular they regard the possibility to administer the vaccine in the first six months of life or by means of maternal immunization in order to give protection to young infants and to avoid the infection during the first months of life.